Neo-DIANA: descriptive results of a prematurely terminated phase II trial of neoadjuvant atezolizumab, chemotherapy and bevacizumab in resectable EGFR-mutated NSCLC

Description

Collazo-Lorduy and co-authors report a trial that recruitment defeat turned into a descriptive paper in this 2026 article: Neo-DIANA, a phase two study of pre-surgical combination therapy for EGFR-mutated lung cancer. The rationale was strong. Tumors carrying EGFR mutations relapse at distant sites after surgery, often in the brain. Yet the landmark chemoimmunotherapy trials excluded these patients. They were seen as poor immunotherapy candidates.

The Spanish multicentre trial planned combination treatment before surgery. Patients would get atezolizumab plus chemotherapy and the vessel-blocking drug bevacizumab. Atezolizumab would then continue afterward. The stages covered were IIIA and IIIB. Slow accrual, reflecting how uncommon resectable EGFR-mutated cases are in Spain, forced premature termination with only a very limited number of patients enrolled, as the authors state plainly. No efficacy conclusions can be drawn, and the paper's real message is about structure. Answering such questions demands international collaboration.

Catalog record

Source: https://europepmc.org/article/MED/PMC13557855